Product Description
A human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, anti-TIGIT monoclonal antibody BMS-986207 binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T cells, and leads to CD226 dimerization and CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-tigit-monoclonal-antibody-bms-986207)
Mechanisms of Action: TIGIT Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: Argentina, Australia, Belgium, Canada, Chile, France, Germany, Israel, Italy, Japan, Poland, Romania, Singapore, Spain, Turkey, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 2: Multiple Myeloma|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CA020-002 | P2 |
Completed |
Small Cell Lung Cancer|Non-Small-Cell Lung Cancer |
2024-01-25 |
45% |
BMS-986207 | P2 |
Active, not recruiting |
Multiple Myeloma |
2023-12-30 |
55% |
CA020-016 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2022-12-27 |
|
2021-000039-29 | P2 |
Completed |
Small Cell Lung Cancer |
2022-12-27 |